Prognostic significance of CD56 expression in patients with multiple myeloma: a meta-analysis

Abstract

Objectives Several studies have demonstrated the expression status of CD56 was associated with prognosis in multiple myeloma (MM) patients, the prognostic significance remains controversial. Here, the prognostic value of CD56 is further investigated in MM patients. Methods We systematically searched the databases including PubMed, EMBASE, Web of Science and the Cochrane Library. The hazard ratios (HRs) with their 95% confidence intervals (CIs) were pooled to evaluate the relationship between CD56 and overall survival (OS) and progress-free survival (PFS). Results A total of 14 studies covering 1365 patients were included in this meta-analysis. The results revealed that CD56 negativity in MM was associated with poorer OS (HR = 1.83, 95% CI = 1.29–2.60, P = 0.001) and PFS (HR = 1.57, 95% CI = 1.27–1.95, P = 0.000). Subgroup analysis further demonstrated that there was an effect of treatment regimen, detection method, survival analysis, study region and the cut-off value of CD56 on CD56 expression. Discussion and conclusion The meta-analysis suggested that CD56 negative patients had a poor prognosis for OS in Asian patients and for PFS in non-Asian patients. Novel drugs didn’t show a significant improvement or overcome on the adverse prognosis brought by CD56 negativity. For patients undergone autologous stem-cell transplantation (ASCT), the poor prognosis was overcome by the treatment, which shed a light on the prognostic judgment and individualized treatment.

Keywords

• multiple myeloma
• cd56
• asct
• novel drugs
• prognosis